Part 2: Synopsis of B-lymphocyte targeted therapy of ANCA-associated vasculitis.
Golbin
J M
JM
Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN 55905, USA.
Specks
U
U
D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000187:drug effects*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008212:Lymphocyte Depletion / Q000379:methods*; D012074:Remission Induction; D000069283:Rituximab; D014657:Vasculitis / Q000276:immunology / Q000628:therapy*
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab